This notion implies that, although favorable results have been reported for clinical studies, the paucity of existing data warrants the need for further ventures in order to further elucidate the favorable effects of GLP-1 in heart failure patients [82]
Any dose reduction strategy represents off-label clinical judgment and should be discussed with your prescribing physician, who may suggest gradually reducing the dose by one step every 46 weeks based on individual circumstances
This is why physician supervision and nutritional coaching are not optional additions to GLP-1 treatment they are what determine whether the results last
Combined SGLT2i and GLP-1RA therapy resulted in a significantly lower risk of all-cause death, non-fatal myocardial infarction, and non-fatal stroke at 12 months than SGLT2i monotherapy (HR, 1.77
demonstrated in a systematic review that adult women with hormonal acne showed significant improvement on spironolactone 50 to 200 mg/day, but outcomes were assessed only during active treatment 1
